Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.62 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.53 |
| ▸ | HPD | P32754 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962142 | 1.00 | MAOB (0.68) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL27555939 | 0.84 | MAOB (0.65) | MAOBNR4A2SRD5A2MAOA | |
| SCHEMBL3658111 | 0.83 | MAOB (0.72) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL3658115 | 0.83 | MAOB (0.72) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL3658118 | 0.83 | MAOB (0.72) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL68983 | 0.81 | MAOB (1.00) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL2498879 | 0.80 | MAOB (0.67) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL2498872 | 0.80 | MAOB (0.67) | MAOBNR4A2SMPD1SRD5A2MAOA | |
| SCHEMBL4961176 | 0.78 | FFAR4 (0.52) | MAOBSMPD1PTPN1CCNB2CDK1 | |
| SCHEMBL4961172 | 0.78 | FFAR4 (0.52) | MAOBSMPD1PTPN1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1114828-B1 | N-ALKYLASPARTYLDIPEPTIDE ESTER DERIVATIVES AND SWEETENERS | AJINOMOTO KK (JP) | 2008-03-12 | — | — | EP | disclosed |
| US-7238830-B2 | N-alkylaspartyl dipeptide ester compounds | AJINOMOTO CO., INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20010039357-A1 | N-alkylaspartyl dipeptide ester compounds | AJINOMOTO CO., INC. (JP) | 2001-11-08 | — | — | US | disclosed |
| EP-1114828-A1 | N-ALKYLASPARTYLDIPEPTIDE ESTER DERIVATIVES AND SWEETENERS | Ajinomoto Co., Inc. (JP) | 2001-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039357-A1 | N-alkylaspartyl dipeptide ester compounds | DNPEP, ANPEP, ASNS | MAOB 4585/4885NR4A2 3653/4885SMPD1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.